title: Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis.
abstract: Acquired and inherited thrombophilic factors increase the risk for (recurrent) venous thrombotic disease. However, little is known about the pathophysiological mechanisms causing these recurrences, or the persistence of thrombosis despite adequate treatment. Because residual thrombosis has been associated with a worse prognostic outcome, we performed an explorative study in order to investigate the prevalence of residual thrombotic lesions after anticoagulant treatment in patients with deep venous thrombosis. Thrombotic parameters as assessed by ultrasonography after a 12-week course of anticoagulants were used. Both thrombophilia in general and acquired thrombophilia in particular were found to be associated with the extent of residual thrombosis. Of the individual thrombophilic factors, protein C deficiency, prothrombin 20210A mutation, active malignant disease and lupus anticoagulant were associated with an increased risk of residual thrombotic mass. Patients with inherited thrombophilia did not differ from patients without any thrombophilic abnormality with regard to residual thrombotic mass [relative risk (RR) 1.3, 95% confidence interval (CI) 0.9-1.8], while acquired thrombophilic disorders increased the risk for residual thrombotic mass as compared to patients without any defect (RR 1.7, 95% CI 1.2-2.2). Although these results should be confirmed in a larger study, they might help us form hypotheses concerning why patients with thrombophilia are more prone to recurrent venous thromboembolic disease.
authors.affiliation: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. I.Bank@amc.uva.nl
authors.forename: Ivan
authors.initials: I
authors.lastname: Bank
authors.forename: Lidwien W
authors.initials: LW
authors.lastname: Tick
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Hutten
authors.forename: Mark H H
authors.initials: MH
authors.lastname: Kramer
authors.forename: Saskia
authors.initials: S
authors.lastname: Middeldorp
authors.forename: Harry R
authors.initials: HR
authors.lastname: Büller
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D005192:Family Health; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor; D008297:Male; D009369:Neoplasms; D017354:Point Mutation; D015995:Prevalence; D020151:Protein C Deficiency; D011516:Prothrombin / Q000235:genetics; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications* / Q000209:etiology; D017211:Treatment Failure; D014463:Ultrasonography; D020246:Venous Thrombosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000628:therapy
chemical_list: D000925:Anticoagulants; D016682:Lupus Coagulation Inhibitor; D011516:Prothrombin